<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Percutaneous transcatheter closure of patent interatrial communications after presumed <z:e sem="disease" ids="C0238096" disease_type="Disease or Syndrome" abbrv="">paradoxical embolism</z:e> is used as an alternative to surgery or long-term anticoagulation for the treatment of patients who are at risk for <z:hpo ids='HP_0004831'>recurrent thromboembolism</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>To avoid atherosclerotic events to be judged as recurrent <z:e sem="disease" ids="C0238096" disease_type="Disease or Syndrome" abbrv="">paradoxical embolism</z:e>, we prospectively excluded <z:hpo ids='HP_0000001'>all</z:hpo> patients with detectable <z:hpo ids='HP_0002634'>arteriosclerosis</z:hpo> from our series and investigated long-term results </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: We report the outcome of 180 patients who underwent percutaneous transcatheter closure of <z:hpo ids='HP_0001655'>patent foramen ovale</z:hpo> (<z:mp ids='MP_0004225'>PFO</z:mp>), <z:mp ids='MP_0004225'>PFO</z:mp> like <z:hpo ids='HP_0001631'>atrial septal defect</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e>), or an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e> because of <z:e sem="disease" ids="C0238096" disease_type="Disease or Syndrome" abbrv="">paradoxical embolism</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>One hundred four patients had <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e>, 57 had <z:hpo ids='HP_0002326'>transient ischemic attacks</z:hpo>, 16 coronary embolism, and 3 had peripheral embolism </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty-three patients experienced multilocal arterial embolism </plain></SENT>
<SENT sid="5" pm="."><plain>One hundred twenty-five patients had a <z:mp ids='MP_0004225'>PFO</z:mp>, 63 of them with an <z:hpo ids='HP_0011995'>atrial septal aneurysm</z:hpo> (<z:chebi fb="37" ids="15365">ASA</z:chebi>), 24 a <z:mp ids='MP_0004225'>PFO</z:mp>-like <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e> (7 of them with an <z:chebi fb="37" ids="15365">ASA</z:chebi>), and 31 had an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>After 18 months, only 5 patients (2.8%) showed a trivial residual shunt </plain></SENT>
<SENT sid="7" pm="."><plain>At a mean follow-up of 40 months (range 4 to 88), resulting in 602 observed patient-years, only 1 patient experienced a presumed paradoxical (coronary) embolism (calculated annual risk to suffer a recurrent thromboembolic event: 0.16%) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Percutaneous transcatheter closure of <z:mp ids='MP_0004225'>PFO</z:mp>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e> is a safe and effective therapeutic option for the secondary prevention of presumed <z:e sem="disease" ids="C0238096" disease_type="Disease or Syndrome" abbrv="">paradoxical embolism</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>It is associated with a high success rate, low incidence of hospital complications, and very low frequency of recurrent systemic embolic events </plain></SENT>
</text></document>